Antibacterial
Spectrum includes:
Gram-positive
aerobes:
Staphylococcus
aureus (including Beta lactamase producing strains),
Staphylococcus saprophyticus,
Streptococcus pneumoniae, Streptococcus pyogenes,
Streptococcus agalactiae,
Streptococcus spp (Groups C, F, G).
Gram-negative aerobes:
Escherichia
coli,
Haemophilus influenzae (including Beta lactamase producing
strains),
Klebsiella pneumoniae,
Moraxella (Branhamella) catarrhalis,
Neisseria gonorrhoeae (including Beta lactamase producing
strains),
Proteus mirabilis,
Citrobacter diversus,
Haemophilus parainfluenzae,
Proteus vulgaris,
Providencia rettgeri.
Anaerobes:
Peptostreptococcus
magnus.
Following
organisms are not susceptible to cefpodoxime proxetil:
Pseudomonas
aeruginosa,
Enterococcus faecalis,
Methicillin resistant Staphylococcus aureus,
Enterobacter spp.
Compositions:
| Spectratil Tablets 100 mg |
| Each
film-coated tablet contains Cefpodoxime proxetil equivalent
to Cefpodoxime 100 mg |
| Spectratil Tablets 200 mg |
| Each
film-coated tablet contains Cefpodoxime proxetil equivalent
to Cefpodoxime 200 mg |
| Spectratil Oral Suspension 100 mg/5 ml |
| Each
5 ml of the constituted suspension contains Cefpodoxime proxetil
equivalent to Cefpodoxime 100 mg. |
Interactions:
Upper
respiratory tract infections:
Acute Maxillary sinusitis,
acute otitis media, tonsillitis and pharyngitis.
Lower
respiratory tract infections:
Acute
bacterial exacerbation of chronic bronchitis and community
acquired pneumonia.
Uncomplicated
skin and skin structure infections:
Abscesses,
wound infections,
cellulites,
furuncle,
subcutaneous abcesses.
Genito-urinary
tract infections:
Acute
uncomplicated urethral and cervical gonorrhoea,
acute uncomplicated ano-rectal infections,
complicated pyelonephritis and complicated cystitis.
Contra-Indications:
Cefpodoxime
proxetil is contraindicated in patients with a known allergy
to Cefpodoxime or to the cephalosporin group of antibiotics.
Side Effects:
The
side effects are mild and transient. GI side effects are
nausea, diarrhoea, vomiting, abdominal pain and colitis.
Occasionally, headache, dizziness, allergic reactions like
hypersensitivity, mucocutaneous reactions, skin rashes and
pruritis, hemolytic disorders like thrombocytosis, thrombocytopenia,
leucopenia ad eosinophilla occur.
Precautions:
Cefpodoxime
proxetil tablets should be used with caution in patients
with previous history of GI disorders like pseudomembranous
colitis.. The presence of Clostridium difficile should be
investigated. During extended therapy (more than 10 days),blood
count should be monitored and treatment should be discontinued
if neutropenia is found.
Warnings:
Cefpodoxime
proxetil tablets should not be given to patients with anaphylactic
response to penicillins. Care should be taken incase of
patients with previous history of hypersensitivity to Cephalosporins.
It should not be used for the treatment of atypical pneumonia
caused by organisms such as Legionella,Mycoplasma and Chlamydia
Drug Interactions:
When
administered along with histamine (H-receptor) blockers
or antacids, approximately 30% plasma concentration of cefpodoxime
decrease due to increase in pH. When administered with probenecid,
plasma levels of cefpodoxime increases. When administered
with compounds of known nephrotoxic potential, close monitoring
of renal function is advised.
Drug/inter laboratory test interactions:
Cephalosporin
induce positive direct Coomb's test.
Pregnancy:
The
results of animal studies in different species indicated that
the drug is not having teratogenic or fetotoxic effects. Since
the safety of the drug in pregnancy was not established, it
should be administered with caution during pregnancy.
Lactation:
The
drug is excreted in human milk. Thus it is recommended that
breast-feeding or treatment of mother with cefpodoxime should
be stopped.
Dosage:
| Adults (>=12 years) |
| Acute exacerbation of chronic bronchitis |
200 mg 12 hourly for 10 days |
| Community acquired pneumonia |
200 mg 12 hourly for 4 days |
| Pharyngitis/tonsillitis |
100 mg 12 hourly for 5-10 days |
| Urinary tract infections |
100 mg 12 hourly for 7-10 days |
| Skin and skin structure infections |
400 mg 12 hourly for 7-14 days |
| Acute uncomplicated gonorrhea |
200 mg single dose |
| Acute Maxillary sinusitis |
200 mg 12 hourly for 10 days |
| Children (2 months—12 years) |
| Acute otitis media |
10 mg/kg/day (max. 400 mg/day in two divided doses) for 5 days |
| Pharyngitis and tonsillitis |
10 mg/kg/day (max. 200 mg/day in two divided doses) for 5—10 days |
| Acute Maxillary Sinusitis |
200 mg 12 hourly for 10 days |
Renal impairment (Adults):
| Creatinine clearance |
Dose and Frequency |
| Less than 30 ml/min |
200 mg every 24 hours |
| Less than 10 ml/min |
200 mg every 48 hours |
| Haemodialysis patients |
200 mg thrice a week after dialysis |
Elderly subjects do not require dosage adjustments unless
they have diminished renal function.
Spectratil is provided as a dry powder for constitution. Add
sufficient boiled and cooled water up to the mark on the label.
Keep the constituted suspension in a refrigerator at 2°
C to 8° C. Constituted suspension should be consumed within
14 days. Shake well before use.
Presentation:
| Spectratil Tablets |
100 mg - Strip of 4's |
| Spectratil Tablets |
200 mg - Strip of 4's |
| Spectratil Oral Suspension |
100 mg/5 ml |
Pexomox
Tablets | LX Tablets
Spectraxime | Spectratil |Spectrazid
|
